Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout
A rivalry between two drugmakers, Cogent Biosciences and Blueprint Medicines, has turned ugly.
Related Articles
Top White House pandemic preparedness official resigns, officials say, in sign of broader disarray
Exclusive: A top White House pandemic preparedness official has resigned, officials tell STAT, in a sign of broader disarray.
Trump nominee for top HHS post pushed to ban methadone treatment
HHS general counsel nominee Mike Stuart’s position on methadone puts him far outside the mainstream in American politics.
Viridian inks deal for autoimmune candidates
And other biotech news updates, brought to you by The Readout.
Most American’s hearts are older than their chronological age, new tool says
According to a new tool that assesses heart health based on standard measures like blood pressure and cholesterol, most Americans are not aging well.
Health care and tech companies promise CMS they’ll make patient data more accessible
Over 60 organizations signed on to a pledge orchestrated by CMS to make health data-sharing easier.
Most American’s hearts are older than their chronological age, new tool says
According to a new tool that assesses heart health based on standard measures like blood pressure and cholesterol, most Americans are not aging well.
Viral infections in the lung, like Covid-19, can reactivate dormant cancer cells
Certain respiratory infections could trigger a reawakening of dormant cancer cells in the body, according to a new study.
Inside the fall of Vinay Prasad at the FDA
Prasad’s departure followed a campaign by a right-wing activist and a controversy over a rare disease drug.